Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05433441

Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

A pilot experiment interventional study is proposed in order to set up multidisciplinary team for Parkinson's patients at home. The aim of this study is to evaluate the effectiveness of this specialized Parkinson's team (ESPark) intervention a on the quality of life of patients with moderate to severe Parkinson's disease

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Pellegrin, Bordeaux, France

Loading trial locations.

About this study

Parkinson's disease (PD) and related disorders are the second most common cause of motor disability in the elderly after stroke. Progressively, the disability impacts the activities of daily living and social life of Parkinson's patients with a major impact on their quality of life. The diversity and complexity of the needs of parkinsonian patients and their caregivers justify a specific multidisciplinary approach. Several studies have evaluated the effectiveness of the intervention of such teams on the maintenance of activities of daily living and quality of life of Parkinson's patients with contradictory results. In France, the experience of specialized Alzheimer teams (ESA) based on the same concept seems to have brought positive results on autonomy and resocialization. Based on the positive experience of ESA intervention in Alzheimer's disease and in view of the data in the literature on Parkinson's disease, we would like to develop the same type of care with teams adapted to the problems of Parkinson's disease patients, which we could call ESParks, and to evaluate the effectiveness of such teams in the context of support for Parkinson's patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For the patient:

  • Patient with a diagnosis of idiopathic Parkinson's disease
  • Patient over 18 years ;
  • Patient with a Hoehn and Yahr Stage greater than or equal to 3;
  • Patient without major cognitive impairment defined by a MOCA score ≥21
  • Patient living at home ;
  • Patient with an identified non-professional primary caregiver;
  • Person affiliated with or benefiting from a social security plan;
  • Free, informed and and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research).

For the caregiver:

  • Male or female over 18 years
  • Able to respond to research interviews/questionnaires
  • Free, informed and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research).

Exclusion criteria

For the patient:

  • Patient with medically indicated dementia impairing comprehension and adherence, and/or with severe confusion or psycho-hallucinatory state;
  • Institutionalized or foster care patients;
  • Patients with a known severe and unstable general pathology that does not allow for patient follow-up;
  • Patients already included in another non-drug management trial;
  • Patients whose institutionalization is envisaged in the short term (within 6 months) or for whom a change of residence is envisaged in the short term and would not allow for follow-up assessments;
  • Patients under guardianship or unable to express consent
  • Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up;
  • Presence of a primary caregiver with a known severe and unstable disease that does not allow for the conduct of the study;
  • Presence of a primary caregiver with a known cognitive or psychiatric disorder (chronic progressive psychosis) that does not allow for the proper conduct of the study.
  • Pregnant or breastfeeding woman.

For the caregiver:

  • Unable to follow the research interviews or questionnaires.
  • Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up;
  • Primary caregiver with a known severe and unstable illness that does not allow for the proper conduct of the study;
  • Primary caregiver with known cognitive or psychiatric disorders (chronic progressive psychosis) that do not allow the study to be conducted properly.

Treatment and study plan

ESPark Intervention

Procedure

The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.

Primary outcomes

  1. Score of quality of life scale (PDQ 39)

    Time frame: Initial Visit - Day 0

    Self-questionnaire in 39 items evaluating the quality of life of Parkinson's patients from a motor and psychological point of view. Each question is rated from 0 (no disturbance) to 4 (maximum disturbance). The items are divided into 8 dimensions (activity of daily living, emotional well-being, psychological discomfort, social support, cognitive impairment, communication, physical discomfort, mobility) It consists of 39 items with a total score that varies from 0 to 154

  2. Score of quality of life scale (PDQ 39)

    Time frame: 6 months

    Self-questionnaire in 39 items evaluating the quality of life of Parkinson's patients from a motor and psychological point of view. Each question is rated from 0 (no disturbance) to 4 (maximum disturbance). The items are divided into 8 dimensions (activity of daily living, emotional well-being, psychological discomfort, social support, cognitive impairment, communication, physical discomfort, mobility) It consists of 39 items with a total score that varies from 0 to 154

Secondary outcomes

  1. IADL assessment

    Time frame: Initial Visit - Day 0

    Assessment of the level of dependence in instrumental activities of daily living It consists of 9 items with a total score that varies from 0 to 36 Each item is scored from 0 (autonom) to 4 (no autonom) or NA

  2. IADL assessment

    Time frame: 6 months

    Assessment of the level of dependence in instrumental activities of daily living

  3. IADL assessment

    Time frame: 12 months

    Assessment of the level of dependence in instrumental activities of daily living

  4. Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rate

    Time frame: Initial Visit - Day 0

    Used to evaluate the various motor and non-motor symptoms. In this protocol, only motor examination will be carried out. This part includes the following items: speech, facial expression, rigidity, finger tapping, hand movements, hand pronation supination movements, toe tapping, leg agility, getting up from the examination chair, walking, postural stability, posture, overall spontaneity of movement, postural hand tremor, hand action tremor, amplitude of resting tremor, constancy of resting tremor. The items of the Parkinsonian triad are evaluated on the different parts of the body (extremities of the limbs, lip and jaw for resting tremor and neck for rigidity). The presence of dyskinesias is mentioned at the end of the evaluation and if they interfered with the motor examination, as well as the global scale of Hoehn and Yahr. All items are rated from 0 to 4 and are clearly defined : 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

  5. Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rate

    Time frame: 6 months

    Used to evaluate the various motor and non-motor symptoms. In this protocol, only motor examination will be carried out. This part includes the following items: speech, facial expression, rigidity, finger tapping, hand movements, hand pronation supination movements, toe tapping, leg agility, getting up from the examination chair, walking, postural stability, posture, overall spontaneity of movement, postural hand tremor, hand action tremor, amplitude of resting tremor, constancy of resting tremor. The items of the Parkinsonian triad are evaluated on the different parts of the body (extremities of the limbs, lip and jaw for resting tremor and neck for rigidity). The presence of dyskinesias is mentioned at the end of the evaluation and if they interfered with the motor examination, as well as the global scale of Hoehn and Yahr. All items are rated from 0 to 4 and are clearly defined : 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

  6. Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rate

    Time frame: 12 months

    Used to evaluate the various motor and non-motor symptoms. In this protocol, only motor examination will be carried out. This part includes the following items: speech, facial expression, rigidity, finger tapping, hand movements, hand pronation supination movements, toe tapping, leg agility, getting up from the examination chair, walking, postural stability, posture, overall spontaneity of movement, postural hand tremor, hand action tremor, amplitude of resting tremor, constancy of resting tremor. The items of the Parkinsonian triad are evaluated on the different parts of the body (extremities of the limbs, lip and jaw for resting tremor and neck for rigidity). The presence of dyskinesias is mentioned at the end of the evaluation and if they interfered with the motor examination, as well as the global scale of Hoehn and Yahr. All items are rated from 0 to 4 and are clearly defined : 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

  7. Non-motor symptoms Scale for Parkinson's Disease (NMSS)

    Time frame: Initial Visit - Day 0

    30-item scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients in all stages of PD.

  8. Non-motor symptoms Scale for Parkinson's Disease (NMSS)

    Time frame: 6 months

    30-item scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients in all stages of PD.

  9. Non-motor symptoms Scale for Parkinson's Disease (NMSS) score

    Time frame: 12 months

    30-item scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients in all stages of PD.

  10. Montreal Cognitive Assessment (MOCA) score

    Time frame: Initial Visit - Day 0

    The MoCA assesses mild cognitive dysfunction. It assesses the following functions: short-term memory, visual-spatial skills, executive functions, attention, concentration, working memory, language, abstraction, calculation and orientation in time and space. Cognitive impairment is assessed using a 30-point score (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; < 10: severe).

  11. Montreal Cognitive Assessment (MOCA) score

    Time frame: 6 months

    The MoCA assesses mild cognitive dysfunction. It assesses the following functions: short-term memory, visual-spatial skills, executive functions, attention, concentration, working memory, language, abstraction, calculation and orientation in time and space. Cognitive impairment is assessed using a 30-point score (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; < 10: severe).

  12. Montreal Cognitive Assessment (MOCA) score

    Time frame: 12 months

    The MoCA assesses mild cognitive dysfunction. It assesses the following functions: short-term memory, visual-spatial skills, executive functions, attention, concentration, working memory, language, abstraction, calculation and orientation in time and space. Cognitive impairment is assessed using a 30-point score (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; < 10: severe).

  13. Beck Depression Inventory (BDI-II) score

    Time frame: Initial Visit - Day 0

    Self-questionnaire comprising a list of 21 items measuring the somatic, affective and cognitive severity of depressive symptoms. Each item is rated for symptom severity and/or frequency, over the past 7 days, on a 4-point scale ranging from 0 to 3. Higher scores indicate severe symptomatology.

  14. Beck Depression Inventory (BDI-II) score

    Time frame: 6 months

    Self-questionnaire comprising a list of 21 items measuring the somatic, affective and cognitive severity of depressive symptoms. Each item is rated for symptom severity and/or frequency, over the past 7 days, on a 4-point scale ranging from 0 to 3. Higher scores indicate severe symptomatology.

  15. Beck Depression Inventory (BDI-II) score

    Time frame: 12 months

    Self-questionnaire comprising a list of 21 items measuring the somatic, affective and cognitive severity of depressive symptoms. Each item is rated for symptom severity and/or frequency, over the past 7 days, on a 4-point scale ranging from 0 to 3. Higher scores indicate severe symptomatology.

  16. Parkinson Anxiety Scale (PAS) Score

    Time frame: Initial Visit - Day 0

    Self-questionnaire assessing anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items). Each item is scored from 0 (not at all) to 4 (strongly or almost always).

  17. Parkinson Anxiety Scale (PAS) Score

    Time frame: 6 months

    Self-questionnaire assessing anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items). Each item is scored from 0 (not at all) to 4 (strongly or almost always).

  18. Parkinson Anxiety Scale (PAS) Score

    Time frame: 12 months

    Self-questionnaire assessing anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items). Each item is scored from 0 (not at all) to 4 (strongly or almost always).

  19. Reduced Neuropsychiatric Inventory (NPI-R) score

    Time frame: Initial Visit - Day 0

    Used to assesses 12 domains of psychobehavioral disorders (21). It is a questionnaire consisting of a screening question and seven to nine items for each of the 12 domains: delusions, hallucinations, agitation/aggressiveness, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor aberration, behavioural disorders, sleep, appetite and eating. The score ranges from 0 to 144 .

  20. Reduced Neuropsychiatric Inventory (NPI-R) score

    Time frame: 6 months

    Used to assesses 12 domains of psychobehavioral disorders (21). It is a questionnaire consisting of a screening question and seven to nine items for each of the 12 domains: delusions, hallucinations, agitation/aggressiveness, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor aberration, behavioural disorders, sleep, appetite and eating. The score ranges from 0 to 144 .

  21. Reduced Neuropsychiatric Inventory (NPI-R) score

    Time frame: 12 months

    Used to assesses 12 domains of psychobehavioral disorders. It is a questionnaire consisting of a screening question and seven to nine items for each of the 12 domains: delusions, hallucinations, agitation/aggressiveness, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor aberration, behavioural disorders, sleep, appetite and eating. The score ranges from 0 to 144 .

  22. Zarit scale score

    Time frame: Initial Visit - Day 0

    This scale assesses caregiver burden ; it consists of 22 items with a total score that varies from 0 to 88. (score ≤20, no burden - score> 60, severe burden).

  23. Zarit scale score

    Time frame: 6 Months

    This scale assesses caregiver burden ; it consists of 22 items with a total score that varies from 0 to 88. (score ≤20, no burden - score> 60, severe burden).

  24. Zarit scale score

    Time frame: 12 Months

    This scale assesses caregiver burden ; it consists of 22 items with a total score that varies from 0 to 88. (score ≤20, no burden - score> 60, severe burden).

  25. State Trait Anxiety Inventory short scale (STAI-E and STAI-T) score

    Time frame: Initial Visit - Day 0

    This anxiety scale consists of 2 scales of 20 questions that assess how subjects feel at the time and generally.

  26. State Trait Anxiety Inventory short scale (STAI-E and STAI-T) score

    Time frame: 6 months

    This anxiety scale consists of 2 scales of 20 questions that assess how subjects feel at the time and generally.

  27. State Trait Anxiety Inventory short scale (STAI-E and STAI-T) score

    Time frame: 12 months

    This anxiety scale consists of 2 scales of 20 questions that assess how subjects feel at the time and generally.

  28. Quality of life as measured by the PQoL Carers.

    Time frame: Initial Visit - Day 0

    Quality of life questionnaire for caregivers Self-questionnaire comprising a list of 26 items with a total score that varies from 0 to 104

  29. Quality of life as measured by the PQoL Carers.

    Time frame: 6 months

    Quality of life questionnaire for caregivers Self-questionnaire comprising a list of 26 items with a total score that varies from 0 to 104

  30. Quality of life as measured by the PQoL Carers.

    Time frame: 12 months

    Quality of life questionnaire for caregivers Self-questionnaire comprising a list of 26 items with a total score that varies from 0 to 104

  31. Sense of competence questionnaire

    Time frame: Initial Visit - Day 0

    This 35-item questionnaire covers three areas: the impact of caregiving on the caregiver's personal life, satisfaction with one's own performance as a caregiver, and satisfaction with the person with dementia as a recipient of care Each item is scored from 1 ("yes") to 3 ("No") and 2 (Yes/no) The total score varies from 27 to 81

  32. Sense of competence questionnaire

    Time frame: 6 months

    This 35-item questionnaire covers three areas: the impact of caregiving on the caregiver's personal life, satisfaction with one's own performance as a caregiver, and satisfaction with the person with dementia as a recipient of care Each item is scored from 1 ("yes") to 3 ("No") and 2 (Yes/no) The total score varies from 27 to 81

  33. Sense of competence questionnaire

    Time frame: 12 months

    This 35-item questionnaire covers three areas: the impact of caregiving on the caregiver's personal life, satisfaction with one's own performance as a caregiver, and satisfaction with the person with dementia as a recipient of care Each item is scored from 1 ("yes") to 3 ("No") and 2 (Yes/no) The total score varies from 27 to 81

  34. Ressource Utilization in Dementia (RUD)

    Time frame: Initial Visit - Day 0

    The questionnaire allows us to estimate the medico-social costs associated with the care of the patient. This estimate is based on the evaluation of the quantity of formal resources (including social services, home care) and informal resources (care and assistance provided by the caregiver) involved in the day-to-day care of the patient; the resources are valued economically using the health insurance rates, where applicable, and the hourly costs of medical and social assistance at home

  35. Ressource Utilization in Dementia (RUD)

    Time frame: 6 Months

    The questionnaire allows us to estimate the medico-social costs associated with the care of the patient. This estimate is based on the evaluation of the quantity of formal resources (including social services, home care) and informal resources (care and assistance provided by the caregiver) involved in the day-to-day care of the patient; the resources are valued economically using the health insurance rates, where applicable, and the hourly costs of medical and social assistance at home

  36. Ressource Utilization in Dementia (RUD)

    Time frame: 12 Months

    The questionnaire allows us to estimate the medico-social costs associated with the care of the patient. This estimate is based on the evaluation of the quantity of formal resources (including social services, home care) and informal resources (care and assistance provided by the caregiver) involved in the day-to-day care of the patient; the resources are valued economically using the health insurance rates, where applicable, and the hourly costs of medical and social assistance at home

Study contacts

Contact information is provided by the study sponsor or research team.

Alexandra FOUBERT-SAMIER, Dr

CONTACT

[email protected]

05 57 82 12 53

Sandrine DUPOUY

CONTACT

[email protected]

05 57 82 14 62

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Evaluation of the Effectiveness of the Parkinson's Specialized Teams Intervention on the Quality of Life of Parkinson's Patients in the Territory of the Nouvelle-Aquitaine and Hauts-de-France: ES-Park Pilot Study.

Acronym: ES-Park

Important dates

Study start
2022
Primary completion
2025
Study completion
2027
First posted
Jun 27, 2022
Registry last updated
Jul 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.